Cargando…
Costs for mitochondrial medicine will remain high as long as mitochondrial disorders are misdiagnosed()()()()
Autores principales: | Finsterer, Josef, Zarrouk-Mahjoub, Sinda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548331/ https://www.ncbi.nlm.nih.gov/pubmed/28819585 http://dx.doi.org/10.1016/j.ymgmr.2017.08.002 |
Ejemplares similares
-
Suspicion of mitochondrial disease remains frequently unconfirmed after whole exome sequencing
por: Finsterer, Josef, et al.
Publicado: (2018) -
Letter to the Editor: Endocrine Compromise in Mitochondrial Disorders
por: Finsterer, Josef, et al.
Publicado: (2018) -
MicroRNAs are inappropriate for characterising hearing impairment in mitochondrial disorders
por: Finsterer, Josef, et al.
Publicado: (2018) -
Treating mitochondrial disorders requires full exploitation of available therapeutic options
por: Finsterer, Josef, et al.
Publicado: (2017) -
Mitochondrial multiorgan disorder syndrome (MIMODS) due to a compound heterozygous mutation in the ACAD9 gene()
por: Finsterer, Josef, et al.
Publicado: (2017)